Figure 7
CD19xTCR DART molecule inhibits B-cell lymphoma. NOD-SCID mice (N = 6-8) were implanted subcutaneously with 1 × 106 Raji cells and 5 × 106 human PBMCs, and then treated IV with the indicated DART molecules on days 1-5. (A) 10μg doses of the CD19xTCR DART molecule effectively blocked tumor growth. (B) With an independent human PBMC donor, 3-μg doses of the CD19xTCR DART molecule blocked tumor growth, whereas no tumor inhibition was observed with a non-B-cell lymphoma DART molecule (HER2xTCR) or in the absence of PBMCs.
